Lv6
2836 积分 2024-06-07 加入
Adverse Events in Targeted Radionuclide Therapy
13天前
已完结
177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial
20天前
已完结
Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using 177Lu-, 90Y-, and 225Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced Malignancies
1个月前
已关闭
Preclinical Development of 3BP-3940, a Fibroblast Activation Protein–Targeted Cyclic Peptide–Based Radiotheranostic for Imaging and Therapy
1个月前
已完结
Feasibility and Therapeutic Potential of 177Lu–Fibroblast Activation Protein Inhibitor–46 for Patients With Relapsed or Refractory Cancers
1个月前
已完结
Phase 1 Dose-Escalation Study of [ 225 Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry
1个月前
已关闭
Phase 1 Dose-Escalation Study of [ 225 Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry
1个月前
已完结
Actinium-225 Targeted Agents: Where Are We Now?
2个月前
已完结
Synthesis and Preclinical Evaluation of Novel 99mTc-Labeled FR-Targeting Agents with Satisfactory Imaging Contrast and Reduced Renal Uptake
3个月前
已完结
Exploration of macrocyclic peptide binders to the extracellular CRD domain of human receptor tyrosine kinase-like orphan receptor 1 (ROR1)
3个月前
已完结
皖公网安备34019202002308
